Related Experiment Videos
Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass
K Kagisaki1, T Masai, K Kadoba
1First Department of Surgery, Osaka University Medical School, Japan.
Insights
Heparin-coated circuits improve biocompatibility in pediatric cardiopulmonary bypass (CPB). These circuits reduced complement activation and inflammatory markers like interleukin-6, suggesting enhanced safety for young patients undergoing CPB.
Area of Science:
- Biomedical Engineering
- Cardiovascular Surgery
- Pediatric Critical Care
Background:
- Pediatric cardiopulmonary bypass (CPB) can trigger inflammatory and complement responses.
- Evaluating biocompatible materials is crucial for minimizing adverse effects during CPB in children.
Purpose of the Study:
- To assess the biocompatibility of heparin-coated CPB circuits in pediatric patients.
- To compare inflammatory and complement activation markers between heparin-coated and conventional CPB circuits.
Main Methods:
- A prospective study involving eight pediatric patients undergoing CPB.
- Patients were divided into a control group (conventional circuits) and a heparin-coated group.
- Blood samples were analyzed for platelet counts, complement activation products (C3a), and inflammatory markers (PIC, TAT, IL-6, IL-8, PMN elastase).
Main Results:
- No significant differences in platelet counts, PIC, or TAT between groups.
- Heparin-coated circuits showed significantly lower C3a levels during and after CPB.
- Reduced levels of PMN elastase during CPB and IL-6 after CPB were observed in the heparin-coated group.
Conclusions:
- Heparin-coated CPB circuits demonstrate superior biocompatibility in pediatric patients.
- These circuits effectively reduce complement system activation and inflammatory responses.
- Heparin coating represents a promising strategy to enhance patient safety during pediatric CPB.
Abstract:
In this study, we evaluated the biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass (CPB). Eight patients were divided into 2 groups: the control group (Group C) and heparin-coated group (Group H). In Group H, CPB circuits, including the arterial pump, oxygenator, and cannulas were heparin-coated. Before, during, and after CPB, blood samples were obtained to assess the platelet counts (Plat), alpha 2-plasmin plasminogen inhibitor complex (PIC), thrombin-antithrombin III complex (TAT), C3 activation products (C3a), interleukin (IL)-6, IL-8, and polymorphonuclear neutrophil leukocyte (PMN) elastase. There was no significant difference in Plat, PIC, or TAT between groups. Group H showed significantly low levels of C3a (during and after CPB), PMN elastase (during CPB), and IL-6 (after CPB). These data demonstrated that in pediatric CPB, heparin-coated CPB circuits reduced the activation of complements and the production of PMN elastase and IL-6, suggesting the superior biocompatibility of the heparin-coated circuits.